Products Categories
| CAS No.: | 359-83-1 |
|---|---|
| Name: | PENTAZOCINE |
| Article Data: | 10 |
| Molecular Structure: | |
|
|
|
| Formula: | C19H27 N O |
| Molecular Weight: | 285.429 |
| Synonyms: | 2,6-Methano-3-benzazocin-8-ol,1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2R,6R,11R)-rel-(9CI); 2,6-Methano-3-benzazocin-8-ol,1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2a,6a,11R*)- (8CI); (?à)-Pentazocine;1,2,3,4,5,6-Hexahydro-3-(3-methyl-2-butenyl)-6,11-dimethyl-8-hydroxy-2,6-methano-3-benzazocine;1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol;2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan;2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol;3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocine;Fortalgesic; Fortalin; Fortral; Fortwin; II-C 2; Lexir; NIH 7958; Peltazon;Pentagin; Pentazocin; Pentazocine; Sosegon; Soseton; Sosigon; Talwin; Win20228; cis-(?à)-Pentazocine;dl-Pentazocine |
| EINECS: | 206-634-6 |
| Density: | 1.036g/cm3 |
| Melting Point: | 145.4-147.20ºC |
| Boiling Point: | 403.5°C at 760 mmHg |
| Flash Point: | 180.8°C |
| Appearance: | Crystalline Solid |
| Hazard Symbols: |
 Xn
|
| Risk Codes: | 22 |
| Safety: | Poison by ingestion, subcutaneous, intramuscular, intraperitoneal, and intravenous routes. Experimental reproductive effects. Human systemic effects by intramuscular and intravenous routes: wakefulness, euphoria, hallucinations or distorted perceptions, tremors, convulsions, excitement, motor activity changes, muscle weakness, analgesia, withdrawal, parasympathomimetic effects, nausea or vomiting, and dermititis. Can cause drug dependency and other central nervous system effects. An analgesic. When heated to decomposition it emits toxic fumes of NOx. See also ALLYL COMPOUNDS. |
| PSA: | 23.47000 |
| LogP: | 3.82050 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
Chemistry
Product Name: 2-(3,3-Dimethylallyl)cyclazocine
The MF of 2-(3,3-Dimethylallyl)cyclazocine (CAS NO.359-83-1) is C19H27NO.
The MW of 2-(3,3-Dimethylallyl)cyclazocine (CAS NO.359-83-1) is 285.42.
Synonyms of 2-(3,3-Dimethylallyl)cyclazocine (CAS NO.359-83-1): (1R,9R,13R)-1,13-Dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0~2,7~]trideca-2,4,6-trien-4-ol ; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan ; Fortalin
Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Agonists;Opioids;Pharmacologicals
Apperance: Crystalline Solid
Index of Refraction: 1.553
EINECS: 206-634-6
Density: 1.036 g/ml
Flash Point: 180.8 °C
Boiling Point: 403.5 °C
Melting Point: 145-147 °C
Uses
2-(3,3-Dimethylallyl)cyclazocine (CAS NO.359-83-1) is used as mixed opioid agonist-antagonist,controlled substance and analgesic (narcotic).
Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| human | LDLo | oral | 18mg/kg (18mg/kg) | LUNGS, THORAX, OR RESPIRATION: BRONCHIECTASIS | Clinical Toxicology. Vol. 10, Pg. 327, 1977. |
| human | TDLo | intramuscular | 571ug/kg (0.571mg/kg) | BEHAVIORAL: EUPHORIA GASTROINTESTINAL: NAUSEA OR VOMITING BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | Journal of Pharmacology and Experimental Therapeutics. Vol. 143, Pg. 149, 1964. |
| human | TDLo | intravenous | 300mg/kg/D (300mg/kg) | BEHAVIORAL: ANALGESIA BEHAVIORAL: WITHDRAWAL | British Medical Journal. Vol. 2, Pg. 21, 1978. |
| mammal (species unspecified) | LD50 | intraperitoneal | 140mg/kg (140mg/kg) | United States Patent Document. Vol. #4205173, | |
| man | TDLo | intramuscular | 83mg/kg/4Y-I (83mg/kg) | MUSCULOSKELETAL: JOINTS | Archives of Internal Medicine. Vol. 143, Pg. 2203, 1983. |
| man | TDLo | intravenous | 3mg/kg/2D-I (3mg/kg) | BEHAVIORAL: WAKEFULNESS BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: EXCITEMENT | Journal of Pharmacology and Experimental Therapeutics. Vol. 143, Pg. 149, 1964. |
| mouse | LD50 | intramuscular | 98mg/kg (98mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 190, Pg. 124, 1971. |
| mouse | LD50 | intraperitoneal | 85mg/kg (85mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ANALGESIA BEHAVIORAL: ATAXIA | Chemical and Pharmaceutical Bulletin. Vol. 24, Pg. 2912, 1976. |
| mouse | LD50 | intravenous | 19800ug/kg (19.8mg/kg) | Drugs in Japan Vol. 6, Pg. 777, 1982. | |
| mouse | LD50 | oral | 305mg/kg (305mg/kg) | Acta Medicia Okayama. Vol. 35, Pg. 179, 1981. | |
| mouse | LD50 | subcutaneous | 140mg/kg (140mg/kg) | Acta Medicia Okayama. Vol. 35, Pg. 179, 1981. | |
| rat | LD50 | intramuscular | 175mg/kg (175mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 190, Pg. 124, 1971. |
| rat | LD50 | intravenous | 21mg/kg (21mg/kg) | "Synthetic Analgesics," Oxford, Pergamon Press, 1966Vol. 2, Pg. 174, 1966. | |
| rat | LD50 | oral | 1110mg/kg (1110mg/kg) | AUTONOMIC NERVOUS SYSTEM: OTHER (DIRECT) PARASYMPATHOMIMETIC BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Kiso to Rinsho. Clinical Report. Vol. 4, Pg. 2145, 1970. |
| rat | LD50 | subcutaneous | 165mg/kg (165mg/kg) | Acta Medicia Okayama. Vol. 35, Pg. 179, 1981. | |
| rat | LD50 | unreported | 280mg/kg (280mg/kg) | BEHAVIORAL: ANALGESIA | Pharmacological Research Communications. Vol. 5, Pg. 175, 1973. |
| women | TDLo | intramuscular | 1400mg/kg/3Y (1400mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: MUSCLE WEAKNESS SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | JAMA, Journal of the American Medical Association. Vol. 231, Pg. 271, 1975. |
Safety Profile
Poison by ingestion, subcutaneous, intramuscular, intraperitoneal, and intravenous routes. Experimental reproductive effects. Human systemic effects by intramuscular and intravenous routes: wakefulness, euphoria, hallucinations or distorted perceptions, tremors, convulsions, excitement, motor activity changes, muscle weakness, analgesia, withdrawal, parasympathomimetic effects, nausea or vomiting, and dermititis. Can cause drug dependency and other central nervous system effects. An analgesic. When heated to decomposition it emits toxic fumes of NOx. See also ALLYL COMPOUNDS.Safety information of 2-(3,3-Dimethylallyl)cyclazocine (CAS NO.359-83-1):
Hazard Codes 
Xn
Risk Statements
R22:Harmful if swallowed.
RTECS PB8750000